Amgen Beats Q4 Expectations Despite FDA Drug Controversy
Amgen (AMGN) reports strong Q4 2025 earnings with $9.87B revenue, beating estimates. Company defies FDA request to withdraw Tavneos while advancing obesity drug MariTide through trials.
NOTRELOAD AI
IonQ Under Fire: Pentagon Contracts May Not Be What They Seem
Short-seller report claims quantum computing company IonQ lost vital Pentagon funding that made up 86% of revenue, acquired non-quantum businesses to hide losses, and insiders sold $397M in stock.
Cumberland Pharma Gets FDA Fast Track for Groundbreaking DMD Heart Treatment
Cumberland Pharmaceuticals receives FDA Fast Track designation for ifetroban, a promising new oral therapy targeting fatal heart disease in Duchenne muscular dystrophy patients.
AbbVie Beats 2026 Profit Forecast Despite Market Concerns Over Drug Portfolio Mix
AbbVie (ABBV) reports strong Q4 earnings and raises 2026 profit outlook to $14.37-$14.57 per share, beating Wall Street estimates, though investors worry about Humira decline and aesthetics challenges.
Oncolytics Biotech Wins FDA Fast Track for Colorectal Cancer Treatment
Oncolytics Biotech receives FDA Fast Track designation for pelareorep in treating KRAS-mutant colorectal cancer, showing promising survival improvements.
Hims Adds Cancer Detection Test to Labs Product
Hims & Hers partners with Grail to offer discounted Galleri cancer detection tests through its Labs subscription service, expanding beyond weight-loss treatments.